Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Ascelia Pharma - Commercial and partnership strategy

By Claus ThestrupCEO, Sweden
Ascelia Pharma

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 17 June 2024 at 10:30 AM.

At this event Julie Waras Brogren will elaborate on the commercial strategy for Orviglance and what investors should expect in terms of partnerships.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. Ascelia Pharma develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmo, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 6/6-2024 12.34.

Recent videos

GreenMobility: What is the investment case in driverless cars
2025-12-05 08:00 GreenMobility
UPM and Sappi are planning a joint venture in graphic papers
2025-12-04 13:00 UPM-Kymmene
GreenMobility: How far away are driverless cars in Denmark
2025-12-04 11:32 GreenMobility
Systemair, Audiocast, Q2'25/26
2025-12-04 09:00 Systemair
Hafnia – Presentation of the quarterly report for Q3 2025
2025-12-02 11:00 Hafnia
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.